CD4 and glioma: Hence, this study suggests that ZIKV can be used as an adjuvant therapy along with vaccination to improve long-term survival of mice with GBM/glioma, as a consequence of CD4+ T-cell response and production of memory T-cells capable of respond selectively to tumor cells.